Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Market Reach
Latest News
Sanofi launches new branding
Marketing: Sanofi has launched a new corporate signature and branding campaign, summing up its mission as 'Empowering Life'.
EBOS takes stake in digital healt biz
Companies: Strategic agreement sees EBOS take a more than 14% share of the digital health leader for close to $10 million.
Gilead set aside $1bn+ for rebates
Reimbursement: In a rare insight into the level of PBS rebates on major drugs, Gilead's 2016 accounts show it set aside more than $1 billion to cover what it expected to pay.
New indications for heart, prostate meds
Regulatory: The TGA has added to approved indications for Sanofi's PCSK9 inhibitor Praluent and prostate cancer treatment Eligard.
Most Popular
Jobs go as Aspen downsizes
Companies: The leading generic supplier is in the middle of a significant round of redundancies that sources say anticipate increased F1 to F2 statutory price cuts.
Wood quits as GBMA boss
Leadership: The Generic and Biosimilar Medicines Association has announced the resignation of CEO Belinda Wood.
Disease awareness ads threatened
Marketing: A proposal by the TGA to revamp rules for S3 ads has potential to confuse disease awareness campaigns says MA.
Dead drug costs Gilead hundreds of millions
Companies: A report to Australia's ASIC reveals just how immensely costly a drug development failure can be, especially when the development company was bought at a premium price.
Janssen scraps two Aust hopefuls
Pipeline: J&J has binned two late-stage drugs - one thought to already be before the TGA - while posting strong Q3 results on the back of pharma division, Janssen.
New drugs boost Roche but biosims loom
Companies: New products Ocrevus, Tecentriq and Alecensa have helped lift sales for Roche as biosim competitors loom for blockbusters Herceptin and Avastin.
TGA appeals for orphan action
Regulation: TGA assistant secretary Adrian Bootes urges pharma companies to push forward the mass of currently unregistered orphan drugs to the ARTG before the designations lapse.
Pharma advertising 'empowers patients'
Scheduling: A new study suggests that different elements in advertising of OTC medicines can actually help patients become more active in their healthcare decision-making.
MSD's cyber losses in hundreds of millions
Cyber Terrorism: Insurers could be up for USD275 million to pay out on losses suffered by MSD (Merck) in the devastating NotPetya virus attack.
NPS MedicineWise goes into film biz
Marketing: NPS MedicineWise is looking for budding film-makers who can excite the public about bacterial resistance to antibiotics.
Approvals Action
New heart pain drug registered
Menarini has registered a new heart pain drug while Sanofi continues to add to Clexane options to address its impending patent expiry.
Pipeline Monitor
Gilead scores first win from Kite buyout
Gilead has received its first FDA approval for newly acquired CAR-T Yescarta following its USD12 billion buyout of original sponsor Kite Pharma in August.
Pharma risks made crystal clear
Once in a while the size of the financial risks inherent in the drug business is made clear and the price of failure emerges as very significant.
FREE Content
Events & Conferences
Pharma in Focus Jobs
lush media